MET and prostate carcinoma: However, recent findings from the phase 3 study in castration-resistant prostate cancer showed no statistically significant improvement in OS with cabozantinib versus prednisone (median OS: 11 versus 9.8 months) [18], indicating that the hypothesis that efficacy in prostate cancer is due to dual inhibition of MET and VEGF may not be justified.